Betaliq
Tampa
About Betaliq
Betaliq is a collaboration between Novaliq, GMBH, and BLP Management Group, LLC. It was formed to develop ophthalmic beta-blockers using Novaliq’s patented EyeSol non-water formulation technology. The company is developing two beta-blockers, for the treatment of glaucoma. BTQ 1901 is an EyeSol based formulation of a potent selective beta-blocker that has not previously been used to treat glaucoma. BTQ 1902 is an EyeSol based formulation of timolol, the most commonly prescribed beta-blockers.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $6.0M
- Funding stage: Seed
- Last round: Seed (Apr 2019)
- Website: betaliq.com
Industries & Categories
Biotechnology, Health Care, Medical
Canonical: https://fsome.com/organization/betaliq-99854 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.